Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement

@article{Lim2010GlucagonlikePP,
  title={Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement},
  author={Jung-Geun Lim and Jang-Jun Lee and Sung-Hee Park and Jae-Hyung Park and Sun-Joo Kim and Ho Chan Cho and Won-Ki Baek and Dae-Kwang Kim and Dae-Kyu Song},
  journal={Neuroscience Letters},
  year={2010},
  volume={479},
  pages={13-17}
}
Bioenergetic deficits are considered a common cause of neurodegenerative diseases. Although creatine supplementation has been shown to be effective in certain neurodegenerative disorders, it is less effective in amyotrophic lateral sclerosis, a disease that primarily affects motor neurons. These neurons are particularly vulnerable to a cellular energy deficit. Using the ATP-depleting drug glucosamine, we evaluated whether the incretin hormone glucagon-like peptide (GLP)-1 protects motor neurons… Expand
Glucagon-like peptide-1 enhances glucokinase activity in pancreatic β-cells through the association of Epac2 with Rim2 and Rab3A.
TLDR
It is suggested that GLP-1 can further potentiate GSIS by enhancing GK activity through the signaling of Epac2 to Rim2 and Rab3A, which is the similar pathway for GLp-1 to potentiate Ca(2+)-dependent insulin granule exocytosis. Expand
Riluzole increases the rate of glucose transport in L6 myotubes and NSC-34 motor neuron-like cells via AMPK pathway activation
TLDR
It is found that riluzole increases the glucose transport rate and up-regulates the translocation of glucose transporters to plasma membrane in both types of cells and can be used to rationally design and synthesize novel anti-ALS drugs that modulate glucose transport in neurons and skeletal muscles. Expand
Cellular glucose availability and glucagon-like peptide-1.
TLDR
The signalling pathways and clinical relevance of GLP-1 in enhancing cellular glucose availability are reviewed, and a mechanism that regulates GLp-1 for glucokinase activity is described. Expand
Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis
TLDR
Ex-4 treatment attenuated neuronal cell death in the lumbar spinal cord, and immunohistochemical analysis demonstrated the rescue of neuronal markers, such as ChAT, associated with motor neurons, in ALS mice treated with Ex-4. Expand
The effects of incretin hormones on cerebral glucose metabolism in health and disease
TLDR
The mechanistics of cerebral glucose transport and metabolism are reviewed, focusing on the deleterious effects of both hypo‐ and hyperglycaemia, and Kinetic studies suggest blood‐brain barrier glucose transport as the key player in GLP‐1 mediated effects on cerebral glucose metabolism. Expand
Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.
TLDR
A model whereby activation of the central GLP-1R reduces food intake via glucose metabolism-dependent inhibition of central AMPK is proposed, which has significant implications given the correlation between sugar consumption and obesity. Expand
Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
TLDR
Evidence supports a neurotrophic and neuroprotective role of GLP‐1 receptor (R) stimulation in an increasing array of cellular and animal neurodegeneration models as well as in neurogenesis, and focuses on the potential benefit of GLp‐1R stimulation as an immediately translatable treatment strategy for acute and chronic neurological disorders. Expand
Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
TLDR
This work aims to integrate the available data on the metabolic and neuroprotective effects of GLP-1 mimetics in the central nervous system (CNS) with the complex crosstalk between T2D-AD, as well as their potential therapeutic value against T1D-associated cognitive dysfunction. Expand
Glucotoxic Mechanisms and Related Therapeutic Approaches.
  • S. Yagihashi
  • Medicine
  • International review of neurobiology
  • 2016
TLDR
In this review, the author summarizes the hitherto proposed theories on the pathogenesis of diabetic neuropathy related to glucose metabolism and future prospects for the effective treatment of neuropathy. Expand
Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway
TLDR
Comprehensive metabolomics analyses identify a novel pathway for diabetic neuropathy that may offer a potential new therapeutic target and explore the mechanism of peripheral nerve injury. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 32 REFERENCES
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.
TLDR
Its ability to lower brain levels of Abeta in mice would appear to be particularly pertinent in this regard, and the ready availability of clinical material and the clinical history of its long term use in subjects with type 2 diabetes would support testing the value of GLP-1R agonists in AD trials. Expand
A new Alzheimer's disease interventive strategy: GLP-1.
TLDR
Data suggest that treatment with GLP-1 or a related peptide beneficially affects a number of the therapeutic targets associated with Alzheimer's disease (AD). Expand
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
TLDR
It is demonstrated that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for exendin-4 in the treatment of stroke and PD. Expand
Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells
TLDR
Investigation of the effects of increased HBP flux on Akt activation in a human astroglial cells line using glucosamine and STZ results in a rapid, short-term phosphorylation of Akt that is likely a result of increased ER stress is indicated. Expand
Class II G protein-coupled receptors and their ligands in neuronal function and protection
TLDR
A better understanding of the cellular and molecular mechanisms by which class II GPCRs signaling modulates neuronal survival and plasticity will likely lead to novel therapeutic interventions for neurodegenerative disorders. Expand
Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases
TLDR
Current literature suggests that exogenous creatine supplementation is most efficacious as a treatment paradigm in Huntington's and Parkinson's disease but appears to be less effective for ALS and Alzheimer’s disease. Expand
Glucosamine Inhibits Glucokinase In Vitro and Produces a Glucose-Specific Impairment of In Vivo Insulin Secretion in Rats
TLDR
It is concluded that glucosamine, probably via a reduction of glucokinase activity, impairs insulin secretion in a manner comparable to that seen in NIDDM. Expand
New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer’s disease?
TLDR
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have very similar properties in protecting neurons from toxic effects, and are capable of reversing the detrimental effects that beta-amyloid fragments have on synaptic plasticity. Expand
GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.
  • J. Buteau
  • Biology, Medicine
  • Diabetes & metabolism
  • 2008
TLDR
This review focuses on the molecular mechanisms by which GLP-1 signaling induces beta-cell mass expansion and acts as a growth factor by promoting beta- cell proliferation, survival and neogenesis. Expand
Mechanisms of action of glucagon-like peptide 1 in the pancreas.
TLDR
Although these latter effects cannot be currently monitored in humans, there are substantial improvements in glucose tolerance and increases in both first phase and plateau phase insulin secretory responses in T2DM patients treated with Ex-4. Expand
...
1
2
3
4
...